Skye Bioscience (NASDAQ: SKYE) is gaining attention due to its lead obesity candidate, nimacimab, currently in Phase 2 trials with results expected in Q3/Q4 2025. Improved earnings and potential short-squeeze setup make this a high-reward opportunity.
Why
SKYE is a Buy:
Bullish Divergence: RSI shows higher lows while price makes lower lows. Stochastic RSI is oversold, indicating potential reversal.
Improved Earnings: Loss per share improved from -$0.28 to -$0.24. Cash position of $68.4 million to fund operations through Q1 2027.
Promising Clinical Trials: Nimacimab targets obesity with up to 16% weight loss in preclinical studies. Positive results expected in late 2025.
Short Squeeze Potential: 12.33% short interest could trigger rapid upward movement.
Analyst Targets: Median price target of $18.00 suggests strong upside potential.
Probability of Success:
$10 Target: 60% - Supported by bullish divergence, earnings, and short interest.
$15 Target: 40% - Achievable with strong momentum and trial results.
Conclusion:SKYE offers a high-risk, high-reward trade opportunity with strong technical signals and promising fundamentals. Watch for volume spikes and further updates on trials.
Why
SKYE is a Buy:Bullish Divergence: RSI shows higher lows while price makes lower lows. Stochastic RSI is oversold, indicating potential reversal.
Improved Earnings: Loss per share improved from -$0.28 to -$0.24. Cash position of $68.4 million to fund operations through Q1 2027.
Promising Clinical Trials: Nimacimab targets obesity with up to 16% weight loss in preclinical studies. Positive results expected in late 2025.
Short Squeeze Potential: 12.33% short interest could trigger rapid upward movement.
Analyst Targets: Median price target of $18.00 suggests strong upside potential.
Probability of Success:
$10 Target: 60% - Supported by bullish divergence, earnings, and short interest.
$15 Target: 40% - Achievable with strong momentum and trial results.
Conclusion:
SKYE offers a high-risk, high-reward trade opportunity with strong technical signals and promising fundamentals. Watch for volume spikes and further updates on trials.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.